Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline

Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877

By: Cassandra Gervolino

Boehringer Ingelheim and Bridge Biotherapeutics Inc. have entered a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877, for patients with fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis (IPF). BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months. 
 
Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit said, “We look forward to working with the team at Bridge Biotherapeutics to develop a new treatment option for patients with IPF.  This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.” 
 
“Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide,” said James Lee, CEO of Bridge Biotherapeutics.
 
“This is a transformational event for Bridge Biotherapeutics with a total potential value in excess of EUR 1.1 billion. It is a testament to the company’s excellence in the development of novel therapeutics for disease areas with high unmet medical need,” commented B. Chris Kim, PhD, a board member of Bridge Biotherapeutics based in Cambridge, Massachusetts.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics